HiberCell

Hiber Cell

Biotechnology, 619 W 54th St Fl 8, New York, 10019, United States, 51-200 Employees

hibercell.com

  • LinkedIn

phone no Phone Number: 65********

Who is HIBERCELL

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity....

Read More

map
  • 619 W 54th St Fl 8, New York, New York, 10019, United States Headquarters: 619 W 54th St Fl 8, New York, New York, 10019, United States
  • 2019 Date Founded: 2019
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from HIBERCELL

HiberCell Org Chart and Mapping

Employees

Ben Harrison

Operations Manager Translational Medicine

Nicole Meinhardt

Clinical Project Manager

Michael Danielson

Executive Director Head of Cmc

Jeremy Drees

Associate Director, Translational Immunology

Trinda Jevne

Clinical Quality Assurance Manager

Alexander Conte

Senior Business Development Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding HiberCell

Answer: HiberCell's headquarters are located at 619 W 54th St Fl 8, New York, 10019, United States

Answer: HiberCell's phone number is 65********

Answer: HiberCell's official website is https://hibercell.com

Answer: HiberCell's revenue is $1 Million to $5 Million

Answer: HiberCell's SIC: 8731

Answer: HiberCell's NAICS: 541714

Answer: HiberCell has 51-200 employees

Answer: HiberCell is in Biotechnology

Answer: HiberCell contact info: Phone number: 65******** Website: https://hibercell.com

Answer: HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access